GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.
You may also be interested in...
NICE’s Nod To Arzerra In CLL A Prelude To Rivalry With Gazyvaro, MabThera
The U.K.’s NICE has given the nod to GSK’s Arzerra (ofatumumab) for first-line CLL, making an eventual rivalry with Roche’s Gazyvaro and potentially revived MabThera a possibility.
CLL Market Snapshot: Seismic Changes Rock The Treatment Landscape
The market for chronic lymphocytic leukemia drugs is undergoing big changes, with three new drugs approved: Roche’s antibody Gazyva and two oral therapies from Pharmacyclics/J&J and Gilead. Side effect profiles, administration and progression-free survival rates are helping to guide treatment decisions.
Payers Come To Terms With Long-Term Coverage Of New CLL Drugs
WellPoint’s new oncology treatment pathway for CLL, released in September, will use higher payments to doctors to steer them to drugs it feels offer the best outcomes and value.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: